Status:
RECRUITING
Visual Perception in Schizophrenia
Lead Sponsor:
University of Rochester
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Schizophrenia Disorders
Bipolar Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study aims to identify novel markers of psychosis using electroencephalography (EEG).
Eligibility Criteria
Inclusion
- All Subjects
- Aged 18-65
- 20/32 visual acuity or better (using in-house optical correction, if necessary)
- An ability to speak English well enough to complete study assessments and to consent to the study
- Subjects with Schizophrenia-Spectrum Disorder
- Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).
- Subjects with Bipolar Disorder
- Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).
Exclusion
- All subjects
- Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:
- Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.
- Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter);
- Actively intoxicated, as shown via patient self-report or staff report;
- Substance use disorder in the past 3 months;
- Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);
- Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation.
- Being in a current manic state
- Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).
- Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;
- Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)
- Lazy eye or squint or other known ocular pathology
- Healthy Control Subjects
- Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);
- Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
- Case-match Control Non-ill Subjects
- Any lifetime psychotic disorder (as assessed by SCID/or SSD);
- Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD)
- Persistent threshold psychotic symptoms
- History of psychiatric hospitalization;
- Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days
- First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.
- Bipolar Subjects
- Persistent threshold psychotic symptoms
Key Trial Info
Start Date :
November 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06911931
Start Date
November 3 2025
End Date
January 31 2027
Last Update
November 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rochester
Rochester, New York, United States, 14642